MAML3-fusions modulate vascular and immune tumour microenvironment and confer high metastatic risk in pheochromocytoma and paraganglioma

This publication has 64 references indexed in Scilit:

• Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
  Annals of Oncology, 2020
• The tumor microenvironment
  Current Biology, 2020
• Recurrent Germline DLST Mutations in Individuals with Multiple Pheochromocytomas and Paragangliomas
  The American Journal of Human Genetics, 2019
• CD8⁺ cytotoxic T lymphocytes in cancer immunotherapy: A review
  Journal of Cellular Physiology, 2018
• Pheochromocytomas and Paragangliomas, Genetically Diverse and Minimalist, All at Once!
  Cancer Cell, 2017
• Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma
  Cancer Cell, 2017
• Current and Future Treatments for Malignant Pheochromocytoma and Sympathetic Paraganglioma
  Current Oncology Reports, 2013
• Plasma methoxytyramine: A novel biomarker of metastatic pheochromocytoma and paraganglioma in relation to established risk factors of tumour size, location and SDHB mutation status
  European Journal of Cancer, 2012
• Recruitment of HIF-1α and HIF-2α to common target genes is differentially regulated in neuroblastoma: HIF-2α promotes an aggressive phenotype
  Cancer Cell, 2006
• The transcriptional repressor Snail promotes mammary tumor recurrence
  Cancer Cell, 2005